دورية أكاديمية
أعرض في EDS

HER2-positive breast cancer: current and future treatment strategies.

التفاصيل البيبلوغرافية
العنوان: HER2-positive breast cancer: current and future treatment strategies.
المؤلفون: Engel RH; Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA., Kaklamani VG
المصدر: Drugs [Drugs] 2007; Vol. 67 (9), pp. 1329-41.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print Cited Medium: Print ISSN: 0012-6667 (Print) Linking ISSN: 00126667 NLM ISO Abbreviation: Drugs Subsets: MEDLINE
أسماء مطبوعة: Publication: Auckland : Adis, Springer International
Original Publication: New York, ADIS Press [etc.]
مواضيع طبية MeSH: Breast Neoplasms/*drug therapy , Receptor, ErbB-2/*analysis, Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/metabolism ; Clinical Trials as Topic/methods ; Clinical Trials as Topic/trends ; Female ; Humans ; Lapatinib ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Quinazolines/therapeutic use ; Receptor, ErbB-2/antagonists & inhibitors ; Trastuzumab ; Treatment Outcome
مستخلص: In the year 2006, breast cancer was estimated to affect >200,000 American women and cause nearly 56,000 deaths. Furthermore, breast cancer is the most common cancer diagnosed and second most common cause of cancer-related deaths in women. The current treatment armamentarium for breast cancer includes chemotherapy, endocrine therapy and biological therapy. Treatment has become more individualised based on characteristics of the tumour including overexpression of the human epidermal growth factor receptor (HER)-2. Between 20 and 30% of all breast cancers overexpress HER2, which means 40,000 - 60,000 patients will have this type of cancer.Previously, overexpression of HER2 was a negative prognostic and predictive risk factor for survival; however, with the advent of trastuzumab, patients' prognosis is improving in all treatment settings. Much controversy exists in the use of trastuzumab, including (i) the sequence of adjuvant trastuzumab (concurrent with chemotherapy or sequential); (ii) the treatment duration (<1 year, 1 year or 2 years); and (iii) the treatment choice upon disease progression (whether to continue or not with trastuzumab and add another cytotoxic agent). Current trials are ongoing to help answer these questions.Furthermore, there has been interest in predicting which HER2-positive patients would require anthracycline therapy, and which could avoid anthracycline therapy and its toxicities. Novel therapeutics, such as lapatinib, an oral tyrosine kinase inhibitor, which blocks both the epidermal growth factor receptor and HER2 receptor has recently been approved by the US FDA. Whereas pertuzumab, a humanised monoclonal antibody, directed against heterodimerisation of HER2 and HER3 has entered phase II and III clinical trials.
Number of References: 95
References: J Clin Oncol. 2006 Sep 10;24(26):4324-32. (PMID: 16896006)
Cancer Res. 2005 Dec 1;65(23 ):11118-28. (PMID: 16322262)
Anticancer Res. 2005 May-Jun;25(3A):1483-9. (PMID: 16033049)
Expert Opin Pharmacother. 2005 Aug;6(9):1555-64. (PMID: 16086643)
J Clin Oncol. 1998 Aug;16(8):2659-71. (PMID: 9704716)
Cancer Cell. 2004 Aug;6(2):117-27. (PMID: 15324695)
Breast Cancer Res Treat. 2007 Mar;102(1):43-9. (PMID: 16897431)
Clin Breast Cancer. 2005 Dec;6(5):425-32. (PMID: 16381626)
N Engl J Med. 2005 Oct 20;353(16):1659-72. (PMID: 16236737)
Cancer. 2003 Jun 15;97(12):2972-7. (PMID: 12784331)
Cancer. 1994 May 1;73(9):2359-65. (PMID: 7909490)
J Clin Oncol. 2002 Feb 1;20(3):719-26. (PMID: 11821453)
J Natl Cancer Inst. 2004 May 19;96(10):739-49. (PMID: 15150302)
Breast Cancer Res Treat. 2007 May;102(3):375-81. (PMID: 17028979)
Cancer Res. 2004 Jun 1;64(11):3981-6. (PMID: 15173011)
J Clin Oncol. 1993 Oct;11(10):1936-42. (PMID: 8105035)
Science. 1989 May 12;244(4905):707-12. (PMID: 2470152)
Cancer Res. 2004 Apr 1;64(7):2343-6. (PMID: 15059883)
In Vivo. 2005 Sep-Oct;19(5):837-40. (PMID: 16097435)
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):845-53. (PMID: 16467098)
J Clin Oncol. 1996 Oct;14(10):2702-8. (PMID: 8874330)
Oncogene. 1995 Jun 15;10(12):2435-46. (PMID: 7784095)
Clin Breast Cancer. 2006 Feb;6(6):535-9. (PMID: 16595039)
N Engl J Med. 2005 Oct 20;353(16):1673-84. (PMID: 16236738)
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30. (PMID: 16514137)
Stem Cells. 1997;15(1):1-8. (PMID: 9007217)
J Clin Oncol. 2002 Apr 1;20(7):1800-8. (PMID: 11919237)
J Clin Oncol. 2006 Jun 20;24(18):2786-92. (PMID: 16782917)
J Clin Oncol. 2006 Jun 20;24(18):2773-8. (PMID: 16682726)
Br J Cancer. 2006 Oct 9;95(7):788-93. (PMID: 16969343)
Exp Hematol. 1999 Oct;27(10):1533-41. (PMID: 10517495)
J Clin Oncol. 2005 Nov 1;23(31):7811-9. (PMID: 16258083)
J Clin Oncol. 2005 Jul 1;23(19):4265-74. (PMID: 15911866)
J Natl Cancer Inst. 2004 May 19;96(10):759-69. (PMID: 15150304)
Nature. 2002 Mar 21;416(6878):279-80. (PMID: 11907566)
Oncol Rep. 2007 Jan;17(1):89-96. (PMID: 17143483)
Genomics. 1989 Apr;4(3):362-6. (PMID: 2565881)
J Clin Oncol. 2005 Apr 10;23 (11):2534-43. (PMID: 15699478)
Adv Exp Med Biol. 2003;532:253-68. (PMID: 12908564)
Cancer Cell. 2004 Apr;5(4):317-28. (PMID: 15093539)
Cancer Res. 2006 Feb 1;66(3):1630-9. (PMID: 16452222)
J Chemother. 2004 Nov;16 Suppl 4:52-4. (PMID: 15688610)
J Clin Oncol. 2005 Aug 10;23(23):5305-13. (PMID: 15955900)
Clin Cancer Res. 2006 Jan 15;12(2):424-31. (PMID: 16428482)
Cancer Res. 1990 Mar 1;50(5):1550-8. (PMID: 1689212)
N Engl J Med. 2001 Mar 15;344(11):783-92. (PMID: 11248153)
Breast Cancer Res Treat. 1998;52(1-3):65-77. (PMID: 10066073)
J Clin Oncol. 1999 Sep;17(9):2639-48. (PMID: 10561337)
J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7. (PMID: 11752009)
Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177-81. (PMID: 2845399)
Ann Oncol. 2005 Nov;16(11):1772-7. (PMID: 16150805)
Anticancer Res. 1992 Mar-Apr;12(2):419-25. (PMID: 1349794)
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9. (PMID: 1350088)
Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100. (PMID: 11236023)
Semin Oncol. 2001 Feb;28(1 Suppl 3):13-9. (PMID: 11301370)
Nat Clin Pract Oncol. 2006 May;3(5):269-80. (PMID: 16683005)
Front Biosci. 2006 May 01;11:1818-43. (PMID: 16368559)
Clin Cancer Res. 2006 Jul 15;12 (14 Pt 2):4436s-4440s. (PMID: 16857824)
N Engl J Med. 2006 Dec 28;355(26):2733-43. (PMID: 17192538)
Cancer Lett. 2006 Feb 8;232(2):123-38. (PMID: 16458110)
Br J Cancer. 2006 Jan 30;94(2):247-52. (PMID: 16404430)
N Engl J Med. 2006 May 18;354(20):2103-11. (PMID: 16707747)
Oncogene. 2005 Sep 15;24(41):6213-21. (PMID: 16091755)
N Engl J Med. 2006 Feb 23;354(8):809-20. (PMID: 16495393)
المشرفين على المادة: 0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
0 (Antineoplastic Agents)
0 (Quinazolines)
0VUA21238F (Lapatinib)
EC 2.7.10.1 (Receptor, ErbB-2)
K16AIQ8CTM (pertuzumab)
P188ANX8CK (Trastuzumab)
تواريخ الأحداث: Date Created: 20070606 Date Completed: 20070820 Latest Revision: 20220331
رمز التحديث: 20240628
DOI: 10.2165/00003495-200767090-00006
PMID: 17547474
قاعدة البيانات: MEDLINE
الوصف
تدمد:0012-6667
DOI:10.2165/00003495-200767090-00006